These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25268876)

  • 1. Respiratory Syncytial Virus: pathology, therapeutic drugs and prophylaxis.
    Gomez RS; Guisle-Marsollier I; Bohmwald K; Bueno SM; Kalergis AM
    Immunol Lett; 2014 Nov; 162(1 Pt A):237-47. PubMed ID: 25268876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies and vaccines against the human respiratory syncytial virus.
    Rivera CA; Gómez RS; Díaz RA; Céspedes PF; Espinoza JA; González PA; Riedel CA; Bueno SM; Kalergis AM
    Expert Opin Investig Drugs; 2015; 24(12):1613-30. PubMed ID: 26457559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
    Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM
    Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.
    Gálvez NMS; Soto JA; Kalergis AM
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8+ T cell immunity against human respiratory syncytial virus.
    Rossey I; Sedeyn K; De Baets S; Schepens B; Saelens X
    Vaccine; 2014 Oct; 32(46):6130-7. PubMed ID: 25223272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.
    Empey KM; Peebles RS; Kolls JK
    Clin Infect Dis; 2010 May; 50(9):1258-67. PubMed ID: 20235830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological management of human respiratory syncytial virus infection.
    Kalergis AM; Soto JA; Gálvez NMS; Andrade CA; Fernandez A; Bohmwald K; Bueno SM
    Expert Opin Pharmacother; 2020 Dec; 21(18):2293-2303. PubMed ID: 32808830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Host Immunity by Human Respiratory Syncytial Virus Virulence Factors: A Synergic Inhibition of Both Innate and Adaptive Immunity.
    Canedo-Marroquín G; Acevedo-Acevedo O; Rey-Jurado E; Saavedra JM; Lay MK; Bueno SM; Riedel CA; Kalergis AM
    Front Cell Infect Microbiol; 2017; 7():367. PubMed ID: 28861397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.
    Rey-Jurado E; Soto J; Gálvez N; Kalergis AM
    Hum Vaccin Immunother; 2017 Sep; 13(9):2092-2097. PubMed ID: 28598702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antiviral efficacy against human respiratory syncytial virus using cotton rat and mouse models.
    Van den Berg J; Kwanten L; Roymans D
    Methods Mol Biol; 2013; 1030():365-72. PubMed ID: 23821282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory damage on respiratory and nervous systems due to hRSV infection.
    Bohmwald K; Espinoza JA; Becerra D; Rivera K; Lay MK; Bueno SM; Riedel CA; Kalergis AM
    Curr Opin Immunol; 2015 Oct; 36():14-21. PubMed ID: 26026788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of a lethal aged mouse model of human respiratory syncytial virus infection.
    Zhang K; Li C; Luo YS; Wen L; Yuan S; Wang D; Ho-Yin Wong B; Zhao X; Chiu MC; Ye ZW; Sun Z; Zhao H; Zhang X; Hu M; Yang D; Shuai H; Wang Y; He J; Bose ME; Henrickson KJ; Huang JD; Zheng B; Chu H; Zhou J
    Antiviral Res; 2019 Jan; 161():125-133. PubMed ID: 30503888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design.
    Rey-Jurado E; Kalergis AM
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liu-He-Tang inhibited plaque formation by human respiratory syncytial virus infection in cell lines of the human respiratory tract.
    Chang JS; Wang KC; Shieh DE; Chiang LC
    J Ethnopharmacol; 2011 Oct; 137(3):1149-55. PubMed ID: 21810459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of Fcγ Receptor-Mediated Immunity to the Pathogenesis Caused by the Human Respiratory Syncytial Virus.
    Acevedo OA; Díaz FE; Beals TE; Benavente FM; Soto JA; Escobar-Vera J; González PA; Kalergis AM
    Front Cell Infect Microbiol; 2019; 9():75. PubMed ID: 30984626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of host adaptive immunity by hRSV proteins.
    Espinoza JA; Bohmwald K; Céspedes PF; Riedel CA; Bueno SM; Kalergis AM
    Virulence; 2014; 5(7):740-51. PubMed ID: 25513775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody development for preventing the human respiratory syncytial virus pathology.
    Soto JA; Gálvez NMS; Pacheco GA; Bueno SM; Kalergis AM
    Mol Med; 2020 Apr; 26(1):35. PubMed ID: 32303184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human and bovine respiratory syncytial virus vaccine research and development.
    Meyer G; Deplanche M; Schelcher F
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):191-225. PubMed ID: 17720245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.
    Bonfanti JF; Roymans D
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):479-87. PubMed ID: 19562644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.